News and Treatment Updates

Here's where you'll find a regularly updated, broad range of articles written by the AAMDSIF team, allied health organizations and news organizations. By staying well-informed, patients and families are practicing a form of self-support that will help them be more effective self-advocates when engaging with health care providers.

Treatment modalities and the impact of granulocyte colony-stimulating factor in AML patients treated with venetoclax and azacitidine: A DATAML registry study

Original Publication Date
Article Source
External Web Content
Abstract Introduction Azacitidine-venetoclax (AZA-VEN) has become a standard treatment in older or chemotherapy-ineligible AML patients. While the registration trial showed a median overall survival (OS) of 14.7 months, most real-world studies have not reproduced this result…

Venetoclax-enhanced reduced-intensity conditioning in older patients aged ≥55 years with high-risk myeloid malignancies undergoing allogeneic peripheral blood stem cell transplantation: A phase II study

Original Publication Date
Article Source
External Web Content
Summary Reduced-intensity conditioning (RIC) is associated with a high relapse rate in high-risk acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS) undergoing allogeneic haematopoietic stem cell transplantation (allo-HSCT). It remains unclear whether venetoclax, an…

Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study 

Original Publication Date
Article Source
External Web Content
Abstract Purpose: To evaluate the efficacy and safety of the cluster of differentiation 47-targeted antibody magrolimab plus azacitidine (Magro/Aza) versus azacitidine alone in treatment-naïve patients with higher-risk myelodysplastic syndromes (MDS) in the phase III ENHANCE…

Impact of Prior Chimeric Antigen Receptor T-Cell Treatment on Graft-Versus-Host Disease and Nonrelapse Mortality After Allogeneic Transplantation

Original Publication Date
Article Source
External Web Content
Highlights •There are no differences in NRM in patients receiving prior CAR T versus no CAR T. •There are no differences in GVHD in patients receiving prior CAR T versus no CAR T. •HCT within 3 months of CAR T had less grades III to IV acute GVHD. ABSTRACT It remains unclear…

Germline predisposition in myeloproliferative neoplasms

Original Publication Date
Article Source
External Web Content
Abstract Myeloproliferative neoplasms (MPNs) were previously thought to result solely from somatic mutations; however, familial clustering and germline genetic testing have revealed hereditary MPNs. These hereditary MPNs are one type of hereditary hematopoietic malignancy (HHM)…

When the Backbone Becomes the Platform: Rethinking Induction in Acute Myeloid Leukemia

Original Publication Date
Article Source
External Web Content
For most of the last 50 years, the conversation with a patient with newly diagnosed acute myeloid leukemia (AML) who is fit for intensive chemotherapy (IC) has followed a familiar script. The goal of therapy is cure, but to achieve this goal, we have to give IC, with the caveat…

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.

We Recommend

For Patients and Families